Related Experiment Videos
[Prostatic acid phosphatase and prostatic specific antigen measured by immunoenzyme assay]
Hinyokika Kiyo. Acta Urologica Japonica
|December 1, 1986
Summary
Prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) are key biomarkers for prostate cancer detection. Elevated levels of PAP and PSA indicate potential malignancy, with values often normalizing after endocrine treatment but rising upon relapse.
Area of Science:
- Urology
- Oncology
- Biochemistry
Context:
- Prostate cancer diagnosis and monitoring rely on specific biomarkers.
- Accurate measurement of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) is crucial for patient management.
Purpose:
- To evaluate the diagnostic utility of PAP and PSA levels in various stages of prostate cancer.
- To assess the correlation of PAP and PSA with tumor grade and benign prostatic hypertrophy.
- To determine the impact of endocrine therapy on PAP and PSA levels.
Summary:
- Abnormal PAP levels were detected in 0% of Stage A1, 0% of A2, 50% of CpN0, 50% of CNX, 0% of D1, and 73% of D2 untreated prostate cancer cases. Abnormal PSA levels were found in 25% of Stage A1, 0% of A2, 50% of CpN0, 100% of CNX, 100% of D1, and 100% of D2 cases.
- Tumor grade did not correlate with PAP or PSA levels. Prostatic hypertrophy showed elevated PAP in 11.1% and PSA in 7.4% of cases.
- PAP and PSA levels were not correlated with each other. Endocrine therapy reduced elevated PAP and PSA in 60% of patients, with levels normalizing during controlled therapy and increasing upon relapse.
Impact:
- These findings highlight the differential sensitivity of PAP and PSA across prostate cancer stages.
- The study underscores the role of PAP and PSA as indicators of treatment response and disease recurrence.
- Understanding biomarker behavior aids in refining prostate cancer monitoring strategies.